New Zealand - English - Medsafe (Medicines Safety Authority)

stevens chemicals ltd - calcium carbonate 324mg; heavy magnesium carbonate 194.4mg; magnesium trisilicate hydrate 64.8mg - tablet - 324mg/194.4mg/64.8mg - active: calcium carbonate 324mg heavy magnesium carbonate 194.4mg magnesium trisilicate hydrate 64.8mg

New Zealand - English - Medsafe (Medicines Safety Authority)

stevens chemicals ltd - calcium carbonate 20%; kaolin 9%; magnesium carbonate 10%; magnesium trisilicate hydrate 10%; sodium bicarbonate 48.5% - powder for oral solution - 20/9/10/10/48.5% - active: calcium carbonate 20% kaolin 9% magnesium carbonate 10% magnesium trisilicate hydrate 10% sodium bicarbonate 48.5%

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

resolution chemicals ltd - azathioprine - oral tablet - 50mg

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - dactinomycin 0.5mg;   - powder for injection - 0.5 mg - active: dactinomycin 0.5mg   excipient: mannitol

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Israel - English - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.